Cargando…

Long-acting muscarinic antagonists vs. long-acting β (2) agonists in COPD exacerbations: a systematic review and meta-analysis

OBJECTIVE: To determine whether long-acting muscarinic antagonists (LAMAs) provide superior therapeutic effects over long-acting β(2) agonists (LABAs) for preventing COPD exacerbations. METHODS: This was a systematic review and meta-analysis of randomized clinical trials involving patients with stab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maia, Israel Silva, Pincelli, Mariângela Pimentel, Leite, Victor Figueiredo, Amadera, João, Buehler, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2017
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687968/ https://www.ncbi.nlm.nih.gov/pubmed/28767773 http://dx.doi.org/10.1590/S1806-37562016000000287

Ejemplares similares

Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β(2)-agonist fixed-dose combinations in COPD
por: Siddiqui, Mohd Kashif, et al.
Publicado: (2019)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
por: Yamada, Hideyasu, et al.
Publicado: (2018)

A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β(2)-Agonist (LABA) Combinations in COPD
por: Sion, Katya Y. J., et al.
Publicado: (2017)

Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with COPD
por: Lee, Eung Gu, et al.
Publicado: (2023)

Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Novel long‐acting antagonists of muscarinic ACh receptors
por: Randáková, Alena, et al.
Publicado: (2018)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
por: Lee, Su Yeon, et al.
Publicado: (2021)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
por: Cazzola, Mario, et al.
Publicado: (2023)

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
por: Ismaila, Afisi Segun, et al.
Publicado: (2015)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis,
por: Sakae, Thiago Mamôru, et al.
Publicado: (2013)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium
por: Katsumata, Mineo, et al.
Publicado: (2022)

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
por: Busse, William W., et al.
Publicado: (2016)

Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis
por: Müllerová, Hana, et al.
Publicado: (2022)

The role of combination therapy with corticosteroids and long-acting β(2)-agonists in the prevention of exacerbations in COPD
por: Cazzola, Mario, et al.
Publicado: (2006)

Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town
por: Hamelmann, Eckard
Publicado: (2018)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Muscarinic Receptor Agonists and Antagonists
por: Broadley, Kenneth J., et al.
Publicado: (2001)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
por: Umeda, Akira, et al.
Publicado: (2023)

Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies
Publicado: (2015)

Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis
por: Hurst, John R, et al.
Publicado: (2018)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
por: Donohue, James F., et al.
Publicado: (2020)

Comparative Causal Analysis of the Effects of Long-Acting Muscarinic Antagonist Versus No Long-Acting Bronchodilator Use on Readmission or Mortality After Hospitalization for Chronic Obstructive Pulmonary Disease
por: Roberts, Melissa H., et al.
Publicado: (2019)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
por: Yang, Hsi-Hsing, et al.
Publicado: (2017)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
por: Tanimura, Kazuya, et al.
Publicado: (2023)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
por: Chapman, Kenneth R, et al.
Publicado: (2014)

Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study
por: Hahn, Beth, et al.
Publicado: (2019)

Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide
por: Price, David, et al.
Publicado: (2015)

Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium*
por: Colthorpe, Paul, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_i11ss3c8gokdvhngfms9vhr4kv